BEFAST: Total Body PET/CT with Ga-68 FAPI for Better Imaging in Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial examines the use of [68Ga]Ga-FAPI-46 Total Body PET/CT in adults with pancreatic or gastroesophageal cancer. Participants are divided into groups based on suspected or confirmed disease and surgical candidacy, with the goal of improving metastatic detection and achieving high-quality images within 30 minutes. The study compares this imaging modality to conventional methods, focusing on diagnostic accuracy and speed. Eligibility requires adult patients with specific pancreatic or gastroesophageal cancer criteria and the ability to consent in Danish. The lead site is Rigshospitalet in Copenhagen, with support from the Danish Cancer Society and Herlev Hospital.

Why it matters

Who can join: the full rules

Inclusion criteria for group A

1. Male or female, over 18 years old
2. Patients with suspected pancreatic cancer based on morphological findings on standard imaging
3. CT or MRI or \[18F\]FDG PET/CT evaluated on MDT with no initial sign of distant metastases
4. Subjects must have been considered suitable for curative surgery at the time of the referral
5. Subjects must be able to read and understand the patient information in Danish to give informed consent

Inclusion criteria for group B1

1. Male or female over 18 years old
2. Histological verified carcinoma from the lower esophagus, GEJ, or stomach
3. Subjects must be considered operable and resectable at the time of referral for MDT
4. Subjects must be able to read and understand the patient information in Danish to give informed consent

Inclusion criteria for group B2

1. Male or female over 18 years old
2. Histological verified SRCC or PCC from the lower esophagus, GEJ, or stomach
3. Subjects with localized disease assigned to perioperative chemotherapy or subjects with metastatic disease assigned to palliative systemic treatment.
4. Subjects must be able to read and understand the patient information in Danish to give informed consent

Exclusion Criteria:

1. Pregnancy or lactation
2. Weight more than the maximum limit of a PET/CT-scanner bed (140 kg)
3. History of allergic reaction due to compounds similar to the chemical composition of \[68Ga\]Ga-FAPI-46

Where it's running

• Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Marie M K Stolberg, MD
• Email: marie.manon.krebs.krarup@regionh.dk
• Phone: +4535454416

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Chronic Stress and Pancreatic Cancer Outcomes in People with Pancreatic Cancer

  This study tests whether ongoing psychological stress affects how pancreatic cancer behaves and responds to treatment in adults.

  Recruiting Shanghai Zhongshan Hospital · Changsha, Hunan and 2 other locations · NCT07529626

• Prehab to get stronger before pancreatic cancer surgery

  This project will test whether adults with pancreatic cancer can follow a combined exercise, nutrition, and symptom-management program during chemotherapy to improve fitness and recovery before surgery.

  Recruiting University of Massachusetts, Worcester · Worester, Massachusetts · NCT07478185

• Surufatinib with Gemcitabine and Nab-paclitaxel as Neoadjuvant Therapy for High-Risk or Borderline Resectable Pancreatic Cancer

  This trial tests whether adding surufatinib to gemcitabine and nab-paclitaxel before surgery helps adults with high-risk resectable or borderline resectable pancreatic cancer.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07436741

• Phase 1 safety and tolerability testing of CTX-10726 in advanced cancers.

  This phase 1 trial will test whether CTX-10726 given by IV every two weeks is safe and tolerable for adults with advanced or metastatic renal cell carcinoma, hepatocellular carcinoma, endometrial, or gastroesophageal cancer who have exhausted standard treatments.

  Recruiting at 8 sites Phase 1 Compass Therapeutics · Phoenix, Arizona and 7 other locations · NCT07419841

• IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors

  This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.

  Recruiting at 23 sites Phase 1 IDEAYA Biosciences · Goodyear, Arizona and 22 other locations · NCT07277413

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.